Roche to embrace new technologies early on

To Roche, scientific breakthroughs are an important source for developing and launching new treatments. Finding the right time to take in new discoveries is a challenge, says William Pao, head of early clinical research at Roche.

Roche Head of Pharma Research and Early Development (pRED) | Photo: Roche / PR

When Roche's division for early research and development enters into new partnerships, this is oftentimes a way of getting new technologies on board – be they new types of immunotherapy, gene therapy or new RNA technologies.

William Pao, who heads Roche's division for early research and development – Pharma Research and Early Development (pRED) – would like to see Roche engage more in such activities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs